Published in Neurology on January 01, 1996
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer (1998) 1.51
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer (2000) 1.07
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer (1997) 1.04
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer (2001) 0.99
Involvement of the peripheral nervous system in primary Sjögren's syndrome. Ann Rheum Dis (2001) 0.88
Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone. Ann Oncol (2008) 0.83
Paraclinical evaluation of side-effects of Taxanes on auditory system. Acta Otorhinolaryngol Ital (2008) 0.83
Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer (2016) 0.80
Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol (2012) 0.80
A Case of Docetaxel Induced Myositis and Review of the Literature. Case Rep Rheumatol (2015) 0.75
Docetaxel neuropathy. Neurology (1996) 0.75
Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project. Breast Cancer Res Treat (2017) 0.75
A prospective study of docetaxel-associated pain syndrome. Support Care Cancer (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med (1995) 6.52
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer (1999) 5.47
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 4.49
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys (1996) 3.42
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer (2002) 3.26
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys (1994) 2.97
Severe head injuries in three countries. J Neurol Neurosurg Psychiatry (1977) 2.91
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res (2001) 2.64
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology (2004) 2.61
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol (2001) 2.52
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Postoperative radiation therapy for rectal cancer. An interim analysis of a prospective, randomized multicenter trial in The Netherlands. Cancer (1991) 2.38
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
[Facial pain due to a lesion in the thorax]. Ned Tijdschr Geneeskd (1992) 2.03
Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med (1990) 1.99
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer (2001) 1.91
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer (1997) 1.88
Cyclosporine neurotoxicity: a review. J Neurol (1999) 1.83
PCV chemotherapy for recurrent glioblastoma multiforme. Neurology (2001) 1.80
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol (1995) 1.61
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res (1992) 1.59
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Role of formulation vehicles in taxane pharmacology. Invest New Drugs (2001) 1.58
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology (2009) 1.57
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res (2000) 1.57
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
Outcome and complications of epidural analgesia in patients with chronic cancer pain. Cancer (1998) 1.56
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene (2012) 1.54
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer (1998) 1.51
The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol (1999) 1.51
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst (1996) 1.49
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology (2011) 1.48
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res (1989) 1.48
Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. Med Decis Making (1994) 1.46
Squamous cell carcinoma of the supraglottic larynx without clinically detectable lymph node metastases: problem of local relapse and influence of overall treatment time. Int J Radiat Oncol Biol Phys (1990) 1.44
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res (1992) 1.44
Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology (1994) 1.43
Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res (1990) 1.43
Neurolymphomatosis of the median nerve. Neurology (1995) 1.42
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR. J Immunol (1987) 1.40
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol (1993) 1.39
[More pain due to pain treatment]. Ned Tijdschr Geneeskd (1993) 1.39
Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol (2001) 1.38
Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patients. Int J Gynecol Cancer (2007) 1.38
[Neuropathic pain; causes and treatment]. Ned Tijdschr Geneeskd (1992) 1.38
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer (2001) 1.37
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol (1994) 1.36
Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol (1997) 1.35
Characterization and use of a digital light projector for vision research. Vision Res (2001) 1.33
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol (1996) 1.33
Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res (1989) 1.32
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer (2003) 1.32
Lessons learned from independent central review. Eur J Cancer (2009) 1.30
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med (1990) 1.29
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther (2007) 1.28
Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology (2004) 1.27